{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Month 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Six patients with Nelson's syndrome met the responder's criteria of attaining normalization or a reduction of more than 50% in primary tumor marker at Month 6.","groups":[{"description":"Nelson's syndrome is associated with local tumor extension or invasion following a therapeutic bilateral adrenalectomy","id":"OG000","title":"Nelson's Syndrome"}],"paramType":"NUMBER","populationDescription":"The efficacy analyzable set included all enrolled patients who received at least one dose of pasireotide LAR and had indication-specific baseline primary biochemical tumor marker levels \\>ULN. Responder analysis are reported only for indications with minimum of 6 patients. Patients with missing Month 6 assessment were considered as non-responders.","reportingStatus":"POSTED","timeFrame":"Baseline, month 6","title":"Nelson's Syndrome: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker","type":"SECONDARY","unitOfMeasure":"Participants"}